Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,662 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum Clear all
Terminated Not applicable Interventional

Enhancing Motivation in Recent Onset Schizophrenia

NCT01817387
View directory record Official record
Conditions
Schizophrenia
Interventions
PRIME, Cognitive Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 29, 2026, 2:18 PM EDT
Completed No phase listed Observational Results available

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

NCT01269710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 19 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

NCT02708940
View directory record Official record
Conditions
Depression, Anxiety, Psychosis
Interventions
Participatory technology development, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia

NCT03697252
View directory record Official record
Conditions
Schizophrenia
Interventions
Xanomeline and Trospium Chloride Capsules, Placebo Capsules
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 60 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 29, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

SPARK Healthy Sleep

NCT07119268
View directory record Official record
Conditions
Schizophrenia and Related Disorders, Sleep Disturbance
Interventions
SPARK Healthy Sleep
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Antidepressant Treatment in Older Adults With Schizophrenia

NCT00047450
View directory record Official record
Conditions
Schizophrenia
Interventions
Citalopram (Celexa), Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
San Diego, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Exercise and Cognitive Training

NCT02326389
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Exercise, Cognitive Remediation
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCT01592110
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
Drug · Other
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 3 Interventional

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

NCT00001768
View directory record Official record
Conditions
Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions
Intravenous immunoglobulin
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 2:18 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

NCT07288567
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT, KarXT Matching Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
13 Years to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
20
States / cities
Anaheim, California • Chino, California • Culver City, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 2:18 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia

NCT06136936
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156-C-001
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 29, 2026, 2:18 PM EDT
Terminated Phase 4 Interventional Results available

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCT02796144
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Overweight
Interventions
Lorcaserin, Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Augusta, Georgia • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 29, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients

NCT00501163
View directory record Official record
Conditions
Schizophrenia, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Fingolimod in Schizophrenia Patients

NCT01779700
View directory record Official record
Conditions
Schizophrenia
Interventions
Fingolimod, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 29, 2026, 2:18 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SPG302 in Adults With Schizophrenia

NCT06442462
View directory record Official record
Conditions
Schizophrenia
Interventions
SPG302, Placebo
Drug
Lead sponsor
Spinogenix
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 2 Interventional

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

NCT01163227
View directory record Official record
Conditions
Schizophrenia Disorders
Interventions
Placebo (single and multiple doses), AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Glendale, California • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCT06372210
View directory record Official record
Conditions
Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Placebo IEM tablet, Abilify MyCite®, D-Tect Patch
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 29, 2026, 2:18 PM EDT
Recruiting Not applicable Interventional

Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment

NCT02916810
View directory record Official record
Conditions
Schizophrenia and Related Disorders
Interventions
Active rTMS stimulation, Sham rTMS stimulation
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 4 Interventional Results available

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCT00982020
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lauderhill, Florida • Bloomfield Hills, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 29, 2026, 2:18 PM EDT
Completed Phase 1 Interventional

BXCL501 for Agitation in Schizophrenia

NCT03708315
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Dexmedetomidine Hydrochloride, Placebos
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 29, 2026, 2:18 PM EDT